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Abstract
Background: Chondrosarcoma has no proven systemic option in the metastatic setting. The development of a non-cross-
resistant strategy, such as cellular immunotherapy using antigen-specific T cells would be highly desirable. NY-ESO-1 and
PRAME are members of the Cancer Testis Antigen (CTA) family that have been identified as promising targets for T cell
therapy. LAGE-1 is a cancer testis antigen 90% homologous to NY-ESO-1, sharing the 157–165 A*0201 NY-ESO-1 epitope
with its transcript variant, LAGE-1s. A number of CTA’s have been induced using 5-Aza-2-Deoxycitabine (5-Aza-dC) in other
cancers. We sought to evaluate the feasibility of targeting chondrosarcoma tumors using NY-ESO-1/LAGE-1s and PRAME
specific T cells using 5-Aza-dC to induce antigen expression.
Methods: We used 11 flash frozen tumors from the University of Washington tumor bank to test for the expression of NY-
ESO-1, PRAME, LAGE-1s and LAGE-1L in chondrosarcoma tumors. Using four chondrosarcoma cell lines we tested the
expression of these CTA’s with and without 5-Aza-dC treatments. Finally, using NY-ESO-1/LAGE-1s and PRAME specific
effectors that we generated from sarcoma patients, we evaluated the ability of these T cells to lyse A*0201 expressing
chondrosarcoma cell lines in vitro both with and without 5-Aza-dC treatment.
Results: A minority (36%) of chondrosarcoma tumors expressed either NY-ESO-1 or LAGE-1s at .10% of our reference value
and none expressed PRAME at that level. However, in all four of the chondrosarcoma cell lines tested, NY-ESO-1 and PRAME
expression could be induced following treatment with 5-Aza-dC including in cell lines where expression was absent or
barely detectable. Furthermore, NY-ESO-1/LAGE-1s and PRAME specific CD8+ effector T cells were able to specifically
recognize and lyse A*0201 expressing chondrosarcoma cell lines following 5-Aza-dC treatment.
Conclusion: These data suggest that adoptive immunotherapy in combination with 5-Aza-dC may be a potential strategy to
treat unresectable or metastatic chondrosarcoma patients where no proven systemic therapies exist.
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Introduction
Chondrosarcoma comprises approximately 20–30% of primary
malignant bone neoplasms with an annual incidence close to 1 in
200,000 person/years. [1]. In the setting of localized disease,
surgery is usually curative [2]. However, in the metastatic setting
or in the case of unresectable disease, prognosis is poor and there
are no proven systemic options [3] [4,5]. The development of a
non-cross-resistant strategy, such as cellular immunotherapy using
antigen-specific T cells would be highly desirable. Antigen specific
adoptive T cell therapy involves the ex vivo selection and
expansion of tumor antigen-specific T cells which can then be
re-infused to treat patients and represents an increasingly effective
modality for the treatment of patients with refractory cancers.
Phase I and II trials of adoptive T cell therapy for metastatic
melanoma have yielded impressive results [6,7,8].
With the exception of synovial sarcoma, the identification of
immunogenic target antigens for sarcomas has not been widely
explored. The family of Cancer Testis Antigens (CTA’s) has been
cited as potential target antigens in sarcomas. These immunogenic
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are not expressed in significant quantities in the normal adult other
than in the testis and placenta [9]. Solid tumor malignancies such
as melanoma have been successfully treated by targeting CTA’s in
early phase immunotherapy trials [8,10]. The NCI Surgery
Branch recently published their experience treating 6 synovial
sarcoma patients using T-cells with a transduced T-cell receptor
targeting NY-ESO-1 [11].
The CTA LAGE-1, which is 90% homologous to NY-ESO-1,
has two transcript variants LAGE-1s and LAGE-1L. The
transcript variant LAGE-1s shares the A*0201 epitope,
SLLMWITQC , with NY-ESO-1 and is thus an equivalent target
for NY-ESO-1 directed therapy. Here, we explore the possibility
of targeting chondrosarcoma using the SLLMQITQC epitope of
NY-ESO-1 (157–165) and LAGE-1s . The expression of another
cancer testis antigen, PRAME, [12,13] and its associated A*0201
epitope ALYVDSLFFL ((300–309) was also evaluated.
Expression of CTA expression can be subject to epigenetic
control and up-regulated using hypo-methylating agents. Of note,
MAGE-A3 induction can be unregulated in lung cancer and
esophageal cancer cell lines using 5-Aza-2-Deoxycitabine (5-Aza-
dC) [14,15] and has been shown to facilitate recognition by NY-
ESO-1 and PRAME specific CTL in several other malignancies
[16,17,18,19]. In a phase I clinical trial of 5-Aza-dC for the
treatment of patients with lung and esophageal cancers, expression
of NY-ESO-1 and MAGE-was up-regulated following treatment
and lasted at least 8 months following therapy [20].
We evaluated if the immunogenic CTA’s, NY-ESO-1, LAGE-
1s and/or PRAME represent feasible targets in chondrosarcoma
for antigen-specific T cell therapy.
Materials and Methods
Tumor Samples and Ethics Statement
All blood and tumor samples used in this study were obtained
under either the Fred Hutchinson Cancer Research Center or the
University of Washington Institutional Review Board approved
protocols. Written consent was obtained from all patients who
contributed samples.
Human chondrosarcoma samples were obtained through the
UW sarcoma tumor bank (IRB approved protocol #21369).
Patients with extra skeletal myxoid chondrosarcoma or synovial
chondromatosis were excluded from analysis. Although some
patients had multiple banked samples, only one sample per patient
was included.
Cell Lines and treatment with 5-Aza-2-Deoxycitabine (5-
Aza-dC)
The chondrosarcoma cell lines JJ, FS and 105KC were gifts of
Dr. Joel Block (Rush University) [21,22]. Cells were maintained in
40% Dulbecco’s modified Eagle’s medium (high glucose), 40%
Minimal Essential Media, 10% F12 (Gibco), 10% fetal bovine
serum plus (Gemini Bio-Products Woodland, CA) 100 nM
hydrocortisone (Sigma, St. Louis, MO), 100 ng/mL insulin
(Gibco) and 25 mg/mL of ascorbic acid and either 0.05 mg/mL
of gentamycin (Gibco) or 50 U/ml penicillin, 50 mg/ml strepto-
mycin (Invitrogen Life Technologies, Carlsbad, CA). The cell line
SW1353 was purchased from American Type Culture Collection
(Manassas, MD) and was maintained in 90% Dulbecco’s modified
Eagle’s medium (high glucose), 10% FBS and 50 U/ml penicillin,
50 mg/ml streptomycin (Invitrogen Life Technologies, Carlsbad,
CA).
The melanoma cell lines Mel A375 (gift from S. Rosenberg) and
Mel 526 (gift from M. Lotze) were used as reference samples and
controls and were maintained in RPMI with Hepes (25 mM), L-
glutamine (4 mM), penicillin (50 U/ml), streptomycin (50 mg/ml),
sodium pyruvate (10 mM), nonessential amino acids (1 mM), and
10% fetal bovine serum (Hyclone, UT, USA). The TAP-deficient
lymphocyte cell line T2 were maintained in RPMI 1640
containing 25 mM HEPES, 2 mM L-glutamine, 50 U/ml peni-
cillin, 50 mg/ml streptomycin (Invitrogen Life Technologies,
Carlsbad, CA), and 10% FBS.
For experiment using 5-Aza-dC, cells were treated with either 5-
Aza-dC 1 mM (dissolved in PBS) or PBS vehicle (control). Media
and either 5-Aza-dC or vehicle were changed every 12 hours for
48 hours and then allowed to rest for 48 hours before RNA
extraction or functional analysis was performed. As a control,
normal PBMC from an otherwise healthy sarcoma patient were
also cultured with 5-Aza-dC and evaluated.
HLA-Typing
High-resolution class I HLA-typing of tumor cell lines and
sarcoma patients considered for leukapharesis was performed by
the Puget Sound Blood Center.
Generation of Antigen Specific Effectors
NY-ESO-1/LAGE-1s and PRAME specific effectors were
generated in our lab from sarcoma patients who were HLA typed
under IRB approved protocol (FCRC protocol #1765) and found
to express A*0201. Patients underwent leukapheresis, also under
IRB approved protocols (FHCRC protocol #1246).
PBMC derived dendritic cells [23] were pulsed with the NY-
ESO-1/LAGE-1s peptide (the 157–165 epitope) SLLMWITQC
or the PRAME peptide (the 300–309 epitope) ALYVDSLFFL.
PBMC were depleted of CD25
+ T cells using the CliniMACS
CD25 MicroBeads (Miltenyi Biotech, Auburn, CA) according to
manufacturer’s instructions and were stimulated using IL-21 as
previously described [24]. MHC tetramers made in our Immu-
nologic Monitoring Core Facilities were used to sort tetramer (See
Figure S1) positive populations which were then expanded using a
Rapid Expansion Protocol [25] in the case of the PRAME specific
cells or cloned and subsequently expanded in the case of the NY-
ESO-1/LAGE-1s specific cells. MART-1 specific effectors were
cloned by the same methods from a melanoma patient.
Quantitative Real Time PCR
RNA was extracted from frozen tumor samples using Trizol
(invitrogen) and from cell lines using RNeasy kit (Qiagen). Because
banked tissue had been obtained under a variety of different
conditions, RNA was checked prior to any analysis using either a
gel or a bioanalyzer prior to ensure it had not degraded before
further analysis was performed. RNA samples were converted to
cDNA using the Transcriptor First Strand cDNA Synthesis Kit
(Roche).
All primers used in these experiments are listed in Table 1.
Initially as a screen to look for LAGE-1, a primer from SA
Biosciences was used (the sequence is proprietary). Subsequently,
we designed specific primers for the two transcript variants LAGE-
1s and LAGE-1L. PRAME specific primers were designed using
the website Primer Depot [26]. Results were analyzed using
GAPDH as a house keeping gene and are calculated relative to
either the cell line MelA375 (NY-ESO-1 and PRAME) or JJ
(LAGE-1s and LAGE-1L) using the standard curve method.
Amplification was performed using SYBR Green PCR Master
Mix (Applied Biosystems, Foster City, Ca) on an ABI 7900HT
(Applied Biosystems, Foster City, Ca).
For all qPCR experiments, the melanoma cell line Mel375 was
used a reference for relative quantification of NY-ESO-1 and
NYESO-1/LAGE-1s and PRAME in Chondrosarcoma
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be lysed specifically by targeting each of these proteins. Similarly,
JJ was selected as a reference for LAGE-1s as it does not express a
significant quantity of NY-ESO-1 and expresses sufficient LAGE-
1s such that it can by lysed using NY-ESO-1/LAGE-1s specific
effectors.
Chromium Release Assay and Cold Target Inhibition
Target cells were labeled with 100 mCi
51Cr and co cultured
with effector cells for 4–6 hours at 37uC plus 5% CO2. To confirm
that the effectors were lysing target tumor cells in an antigen
specific fashion, cold target inhibition was performed [27].
Chromium labeled 5-Aza-dC treated tumor lines were incubated
with non-radiolabelled T2 lymphocytes which were either
unpulsed (control), pulsed the PRAME peptide, ALYVDSLFFL,
or pulsed with the NY-ESO-1 peptide SLLMWITQC. Ratios of
30:1 and 10:1 unlabeled to
51Cr labeled targets were used [27].
E:T ratios of 30:1 were used. Conditions were otherwise similar to
the other chromium release assays performed.
Statistical Considerations
All in vitro experiments were repeated at a minimum of three
times to be sure results were reproducible. Standard errors and p-
values (calculated using student’s T test) are calculated using
multiple data points within a single representative experiments
done in either triplicate or quadruplicate.
Results
A Minority of Chondrosarcoma Tumors Express Either
LAGE-1s or NY-ESO-1
In order to characterize the expression pattern of NY-ESO-1,
LAGE-1s and PRAME in chondrosarcoma tumors, we used qRT-
PCR to test the tumors of eleven chondrosarcoma patients
(Table 2).
Four of the 11 tumors had detectable expression of NY-ESO-1
however in all but one case, the level of expression was less than
2% of the reference sample Mel375 (in 2 of the cases it was less
than 0.1% of the reference sample). There was one tumor that
expressed NY-ESO-1 at over 15% of the reference samples.
PRAME expression was similarly low, with detectable expression
seen in 7 of the samples but at levels not more than 10% relative to
Mel 375 in any of the samples.
There were three samples (27%) that had quantitative
expression of LAGE-1s that was .10% with respect to the
reference sample JJ. LAGE-1L was also examined (not shown) and
the same 3 patients were the only patients with .10% expression
of LAGE-1L compared to the reference sample. LAGE-1L does
not share the SLLMWITQC epitope with NY-ESO-1 and LAGE-
1s.
In summary, a total of four of eleven (36%) patients examined
expressed either NY-ESO-1 or LAGE-1s at a quantitative level
that might be suitable for targeting using antigen specific T cells
targeting the HLA-A2-restricted NY-ESO-1/LAGE-1s epitope:
SLLMWITQC.
NY-ESO-1, PRAME and LAGE-1s Can be Up regulated in
Chondrosarcoma Cell Lines Using 5-Aza-2-Deoxycitabine
To broaden the eligibility of potential chondrosarcoma patients
for NY-ESO-1 and PRAME specific T-cell therapy, we evaluated
whether 5-Aza-dC could be used to up-regulate these antigens in
chondrosarcoma cell lines, FS, JJ, 105KC and SW1353.
Table 1. qRT-PCR primers used for these experiments.
Gene Sequence Reference
NY-ESO-1 59-TGCTTGAGTTCTACCTGCCA-39 [39]
59-TATGTTGCCGGACACAGTGAA-39
PRAME 59-GCTTCAAAATGGAACGAAGG-39 from primer depot:
[26]
59-TGCCAGCTCCACAAGTCTC-39
LAGE-1s 59-CGCCCATGGAAGCGGAGCTG-39 designed for these
studies
59-CTGCAGCAGTCAGTCGGATAAACA-39
LAGE-1L 59-TGCTTCAGTTGCACATCACGATGC-39 designed for these
studies
59-TGGTCCCGAACTGACATAAACAGTAGG-39
GAPDH 59-GAAGGTGAAGGTCGGAGTC-39 [40]
59-GAAGATGGTGATGGGATTTC-39
doi:10.1371/journal.pone.0032165.t001
Table 2. qRT-PCR results on flash frozen chondrosarcoma tumors from the UW Sarcoma Tissue Bank relative to positive Control
Cell Lines Mel375 (for NY-ESO-1 and PRAME) and JJ (For LAGE-1s).
Patient Histology Patient Outcome NY-ESO PRAME LAGE-1s
1 Conventional Chondrosarcoma Grade 2/3 metastatic disease 0.0% 0.1% 0.0%
2 Clear cell chondrosarcoma grade 1/3 metastatic disease 0.0% 0.2% 21.7%
3 Conventional chondrosarcoma grade 2/3 locally recurrent 0.0% 0.0% 0.3%
4 conventional chondrosarcoma grade 3/3 metastatic disease 1.5% 0.0% 68.7%
5 Conventional Chondrosarcoma low grade (1/3) disease free 0.0% 0.2% 17.4%
6 Conventional Chondrosarcoma grade 2/3 disease free 15.4% 0.0% 0.0%
7 Dedifferentiated Chondrosarcoma (high grade) metastatic disease 0.0% 3.4% 0.0%
8 Conventional Chondrosarcoma grade 3/3 metastatic disease 0.0% 0.0% 0.0%
9 Conventional Chondrosarcoma Grade 2/3 disease free 0.0% 0.0% 1.0%
10 Conventional Chondrosarcoma grade 2/3 local recurrence 0.0% 0.0% 0.0%
11 Conventional Chondrosarcoma grade 1/3 local recurrence 0.0% 0.0% 0.0%
doi:10.1371/journal.pone.0032165.t002
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each of the four cell lines. Of note, in cell line FS, NY-ESO-1 was
undetectable prior to treatment but increased to levels even higher
than the reference sample following 5-Aza-dC treatment
(Figure 1A). The cell line SW1353 expressed NY-ESO-1 at
baseline when untreated and further increased expression
following 5-Aza-dC treatment. The cell line 105KC had weak
but detectable levels of NY-ESO-1 and the cell line JJ had barely
detectable NY-ESO-1 expression (less than 0.0001 relative to
Mel375). Both of these cell lines had multiple log fold increases in
NY-ESO-1 expression following 5-Aza-dC treatment.
Similar increases were seen with regards to expression of
PRAME (Figure 1B). Much like our clinical samples, in each cell
line at baseline PRAME expressed in the untreated cell lines at a
relatively low level. However PRAME expression was increased
significantly following 5-Aza-dC treatment including the cell lines
FS, which had increased expression above the level of the
reference sample. The cell line JJ had expression of PRAME
increase to near the level of the reference sample.
Both the cell line JJ and 105KC express significant amounts of
LAGE-1s without treatment and expression was not significantly
increased following 5-Aza-dC treatment. The cell line FS does not
express LAGE-1s but expression was induced following 5-Aza-dC
treatment. The cell line SW1353 had a low level of expression
which increased following treatment (Figure 1C). Of note, LAGE-
1L expression was also increased/induced in these cell lines
including the cell line FS which had undetectable expression at
baseline (data not shown).
Of note, normal PBMC from an otherwise healthy sarcoma
patient were treated with 5-Aza-dC. Both NY-ESO-1 and
Figure 1. qRT-PCR expression in the chondrosarcoma cell line FS, JJ, 105KC and SW1353 with and without treatment using 5-Aza-
dC for 48 hours. Treated cells rested 48 hours prior to RNA extraction. Primers are listed in Table 1. Data is presented relative to a reference sample:
either Mel375 for NY-ESO-1 and PRAME or JJ for LAGE-1s normalized to GAPDH. Asterisk indicates statistical significance of p,0.05. Note that all CT
antigens were significantly increased following 5-Aza-dC in all chondrosarcoma lines with the exception of LAGE-1s expression in the 105KC and JJ.
These cell lines both strongly expresses LAGE-1s without treatment and were not changed significantly by 5-Aza-dC. The JJ cell line is not displayed in
1C as it is used for a reference value for LAGE-1s. Error bars describe variation between multiple values within a single experiment. Experiments were
repeated at least three times to ensure reproducibility.
doi:10.1371/journal.pone.0032165.g001
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samples. This is consistent with what has also been seen in normal
fibroblast cell lines [28].
5-Aza-dC Increases Antigen Specific Recognition and Cell
Lysis in Chondrosarcoma Cell Lines Treated with NY-ESO-
1/LAGE-1s and PRAME Specific Effectors
T cell epitopes for several CTAs have been identified for HLA-
A*0201, which is expressed in more than 40% of individuals. High
resolution class I typing of all four chondrosarcoma cell lines and
revealed that the FS and JJ cell lines both were positive for A*0201.
The cell lines 105KC and SW1353 did not express A*0201 and
were thus excluded from functional analysis using A*0201 positive
effectors.
The cell line FS does not express NY-ESO-1 or LAGE-1s. Even
at high E:T ratios such as 100:1 (not shown) no lysis was seen in
this cell line using specific NY-ESO-1/LAGE-1s (SLLMWITQC)-
specific CTL. Like FS, the cell line JJ line does not express
significant constitutive levels of NY-ESO (barely detectable
expression ,0.001% of Mel375), however it does express high
levels of LAGE-1s and the cell line was readily lysed using the NY-
ESO-1/LAGE-1s specific effectors. Even at E:T ratios as low as
10:1 over 30% specific lysis (Figure 2A) was seen.
The use of 5-Aza-dC was found to significantly enhance NY-
ESO/LAGE-1s mediated killing in the FS cell line compared to
cells treated with vehicle alone. Using 5-Aza-dC treated FS targets
were lysed over 10% at all E:T ratios examined and over 20% at
the 40:1 E:T ratio. The JJ cell line which was lysed even without
treatment, was further sensitized to lysis follow 5-Aza-C treatment
at low E:T ratios however at higher E:T ratios lysis was not
increased significantly as lysis of JJ was higher at the higher E:T
ratios with out much change in the lysis of the treated JJ cells. The
fact that significantly increased lysis was not seen at high E:T ratios
see probably represents a maximum lysis that can be detected for
the JJ cell line with these effectors in the given conditions
(Figure 2B).
Using a PRAME specific CTL line, less then 10% of targets
were lysed in the untreated JJ and FS cell lines reflecting the low
levels of expression seen by qRT-PCR. Following treatment with
5-Aza-dC, increased lysis was seen with both cell lines (Figure 2C
and 2D).
In order to confirm that CTL mediated lysis of 5-Aza-dC
treated tumor targets were lysed specifically, cold target inhibition
was performed (Figure S2). Using both NY-ESO-1 and PRAME
specific effectors, lysis of 5-Aza-dC treated JJ and FS was inhibited
by peptide pulsed cold targets at the 30:1 cold to hot target ratio
and to lesser extent at the 10:1 cold to hot target ratio compared
with unpulsed controls.
Discussion
While expression patterns of Cancer Testis Antigens are being
increasingly well described in a number of malignancies [29,30],
Figure 2. Chromium Release using two A*0201 expressing chondrosarcoma cell lines: FS and JJ. Asterisks indicate statistical significance
of p,0.05. Each cell line had significantly increased lysis using antigen specific effectors following treatment with 5-Aza-dC with the exception of JJ in
combination with NY-ESO-1/LAGE-1s effectors at high E:T ratios. JJ is highly sensitive to NY-ESO-1/LAGE-1 specific effectors without 5-Aza-dC
treatment and the fact that increased lysis was not seen at high E:T ratios probably represents a maximum lysis that can be detected for the JJ cell
line with these effectors in the given conditions. To control against non-specific cell lysis, targets were tested with a MART-1 specific CTL clone used
at an E:T ratio of 25:1. Minimal killing was seen testing the control effectors against either treated or untreated targets. No cell line had increased lysis
following 5-Aza-dC treatment using the control MART-1 effectors (p.0.1). To be sure the MART-1 specific cells were effective, we also targeted the
MART-1 expressing cell line Mel526 during each experiment resulting in over 40% lysis (not shown). Error bars describe variation between multiple
values within a single experiment. Experiments were repeated at least three times to ensure reproducibility.
doi:10.1371/journal.pone.0032165.g002
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chondrosarcoma in particular [12]. Chondrosarcoma is frequently
treatable in the localized setting but for patients with locally
advanced/unresectable or metastatic disease there are no proven
systemic options. Moreover, high grade and dedifferentiented
chondrosarcoma have a high risk of recurrence following resection
and this minimal residual disease setting following resection may
be the ideal setting for immunotherapies.
Other studies have suggested that immunotherapy could be
used to treat chondrosarcoma patients [31,32]. Indeed lysis of the
FS cell line using MAGE-A3 effectors has been documented as has
the coexpression of CSAGE along with MAGE-A family antigens
[33,34] though MAGE-A family expression in chondrosarcoma
tumors has not been demonstrated at the protein level.
This study is the first to report the targeting of NY-ESO-1/
LAGE-1s and/or PRAME in chondrosarcoma. Furthermore the
use of 5-Aza-dC to target chondrosarcoma in combiation with
antigen-specific immunotherapy is presented for the first time
[35,36].
We report that while a minority of chondrosarcoma patients can
be targeted using NY-ESO-1/LAGE-1s or PRAME specific
effectors, it may be feasible to broaden the pool of eligible patients
by upregulating expression and by enhance targeting of endog-
enously expressed antigen on tumor cells by pretreatment with
59Aza-2-Deoxycitadine, (Decitabine), a drug with a well-docu-
mented side effect profile (without known autoimmune toxicity)
that is considered relatively non-toxic [37].
In murine models, cancer testis antigens are inducible [38] and
increased expression has been demonstrated (although antigen
presentation has not yet been documented) in human cancer
patients in the case of esophageal cancer and lung cancer [20].
These data suggest that adoptive immunotherapy in combination
with 5-Aza-dC may be a potential strategy to treat unresectable or
metastatic chondrosarcoma patients where no proven systemic
therapies exist.
Supporting Information
Figure S1 Tetramer and CD8 staining demonstrating
tetramer positive populations after CD25 depleted cells
are stimulated twice using dendritic cells pulsed with
peptide. Cells were then sorted using tetramer. Cells that were
positive for PRAME tetramer were expanded after sorting; cells
positive for NY-ESO tetramer were cloned and expanded after
sorting.
(PDF)
Figure S2 5-Aza-dC treated cells from the JJ or FS cells
lines were incubated with NY-ESO-1 or PRAME specific
effectors along with un-pulsed (control) or peptide pulse
T2 lymphocytes. Killing of the chromium labeled tumor cell
lines was completely inhibited at the ratio of 30:1 cold to hot
targets. Killing was also inhibited to a lesser extent at the 10:1 cold
to hot ratio.
(PDF)
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